Where to Buy GLP-1 Medications in 2026: Retail Pharmacies, Telehealth Platforms, and Compounded Options Explained

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• GLP-1 medications require a prescription from a licensed provider in all 50 states; no legitimate over-the-counter or online-only purchase options exist
• Brand-name GLP-1s (Ozempic, Wegovy, Mounjaro, Zepbound) are available through retail pharmacies with insurance or manufacturer savings cards; cash prices range from $935 to $1,349 per month
• Compounded semaglutide and tirzepatide are legal alternatives during FDA-declared shortages, available through telehealth platforms at $297 to $499 per month, but are not FDA-approved and not interchangeable with brand products
• The FDA shortage list changes monthly; as of April 2026, semaglutide remains on shortage while tirzepatide availability has stabilized in some formulations

Direct answer (40-60 words)

GLP-1 medications are prescription-only drugs available through three channels: retail pharmacies (CVS, Walgreens, independent pharmacies) for brand-name products with insurance or savings programs; telehealth platforms that prescribe and ship compounded versions during FDA shortages; and specialty compounding pharmacies with a provider's prescription. All legitimate sources require a licensed provider evaluation first.

Table of contents

1. The three legal pathways to buy GLP-1 medications
2. Retail pharmacy: brand-name products, insurance, and savings cards
3. Telehealth platforms: how prescription, compounding, and shipping work
4. Compounding pharmacies: direct access and provider requirements
5. What most articles get wrong about "buying GLP-1 online"
6. Price comparison: brand vs compounded across all channels
7. The FDA shortage list and what it means for your options
8. Insurance coverage patterns in 2026
9. The FormBlends sourcing decision tree
10. When compounded is appropriate vs when brand-name is required
11. Red flags: how to spot illegitimate sellers
12. FAQ
13. Sources

The three legal pathways to buy GLP-1 medications

Every legitimate GLP-1 purchase in the United States follows one of three pathways. All three require a prescription from a licensed provider. No exceptions exist.

Pathway 1: Retail pharmacy with brand-name prescription. Your provider writes a prescription for Ozempic, Wegovy, Mounjaro, Zepbound, or Rybelsus. You fill it at CVS, Walgreens, Walmart, Costco, or an independent pharmacy. Insurance may cover part or all of the cost. If paying cash, manufacturer savings cards can reduce the price to $25 to $550 per month depending on the product and your insurance status.

Pathway 2: Telehealth platform with compounded prescription. You complete an online medical intake. A licensed provider reviews your information and, if appropriate, prescribes compounded semaglutide or tirzepatide. The platform partners with a state-licensed compounding pharmacy that prepares your medication and ships it to your home. This pathway is legal only when the FDA has declared a shortage of the corresponding brand-name drug.

Pathway 3: Compounding pharmacy with provider prescription. Your own provider (primary care, endocrinologist, obesity medicine specialist) writes a prescription for compounded semaglutide or tirzepatide. You send the prescription to a compounding pharmacy directly. The pharmacy ships the medication to you. This pathway also requires an active FDA shortage declaration.

The distinction matters because the FDA's shortage list changes monthly. When a drug moves off shortage, compounding pharmacies are required to stop producing that formulation within a defined transition period. As of April 2026, semaglutide (the active ingredient in Ozempic and Wegovy) remains on the FDA shortage list. Tirzepatide (Mounjaro and Zepbound) was removed from shortage in February 2025 for some dose strengths but remains on shortage for others, creating a complex sourcing landscape.

Retail pharmacy: brand-name products, insurance, and savings cards

Brand-name GLP-1 medications are manufactured by Novo Nordisk (semaglutide products) and Eli Lilly (tirzepatide products). These are FDA-approved drugs that have undergone the full clinical trial and review process.

Available products and indications:

Product	Active ingredient	FDA indication	Available doses
Ozempic	Semaglutide	Type 2 diabetes	0.25, 0.5, 1, 2 mg weekly
Wegovy	Semaglutide	Obesity (BMI ≥30 or ≥27 with comorbidity)	0.25, 0.5, 1, 1.7, 2.4 mg weekly
Rybelsus	Semaglutide (oral)	Type 2 diabetes	3, 7, 14 mg daily tablets
Mounjaro	Tirzepatide	Type 2 diabetes	2.5, 5, 7.5, 10, 12.5, 15 mg weekly
Zepbound	Tirzepatide	Obesity (BMI ≥30 or ≥27 with comorbidity)	2.5, 5, 7.5, 10, 12.5, 15 mg weekly

Cash pricing (April 2026 averages):

• Ozempic: $968.52 per month (4 weekly doses)
• Wegovy: $1,349.02 per month
• Rybelsus: $935.77 per month (30 tablets)
• Mounjaro: $1,023.04 per month
• Zepbound: $1,059.87 per month

Source: GoodRx aggregated retail pharmacy pricing data, April 2026.

Insurance coverage: Most commercial insurance plans cover GLP-1 medications for their FDA-approved indication. Coverage for diabetes (Ozempic, Mounjaro, Rybelsus) is broader than coverage for obesity (Wegovy, Zepbound). A 2025 analysis by the Peterson-KFF Health System Tracker found that 67% of employer-sponsored plans cover at least one GLP-1 for diabetes, while only 27% cover GLP-1s for obesity (Whaley et al., Health Affairs 2025).

Medicare Part D plans vary widely. Traditional Medicare does not cover weight-loss medications, but some Medicare Advantage plans added GLP-1 obesity coverage in 2024 and 2025. Medicaid coverage depends on state policy; 14 states cover GLP-1s for obesity as of April 2026.

Manufacturer savings programs: Both Novo Nordisk and Eli Lilly offer savings cards that reduce out-of-pocket costs for patients with commercial insurance. These programs typically cap your copay at $25 to $150 per month. The programs exclude patients on government insurance (Medicare, Medicaid, Tricare).

Novo Nordisk Savings Card (Ozempic, Wegovy): up to $500 off per 30-day fill for commercially insured patients. Wegovy-specific card offers $500 off for up to 13 fills.

Lilly Savings Card (Mounjaro, Zepbound): $25 per month for commercially insured patients, up to $550 in savings per fill.

The catch: these cards work only if your insurance covers the medication. If your plan excludes the drug entirely, the savings card usually cannot be applied to the full cash price. Some plans have learned to structure their formularies to block savings card use, a practice called "copay accumulator programs."

Telehealth platforms: how prescription, compounding, and shipping work

Telehealth platforms emerged as the dominant access point for compounded GLP-1 medications during the 2022 to 2026 shortage period. The model works like this:

1. Medical intake. You complete an online questionnaire covering medical history, current medications, weight, height, previous weight-loss attempts, and contraindications. Some platforms require photo ID and a short video consultation; others use asynchronous provider review.

1. Provider review. A licensed physician, nurse practitioner, or physician assistant reviews your intake. The provider is licensed in your state of residence. If you meet clinical criteria (typically BMI ≥27 with a weight-related comorbidity or BMI ≥30), the provider writes a prescription for compounded semaglutide or tirzepatide.

1. Compounding and shipping. The prescription is sent to a partner compounding pharmacy licensed in your state or a state with reciprocal agreements. The pharmacy compounds the medication (usually as a lyophilized powder requiring reconstitution, or as a pre-mixed liquid in a vial). The medication ships via temperature-controlled courier, typically arriving within 3 to 7 days.

1. Ongoing monitoring. Most platforms include follow-up check-ins (monthly or quarterly) to assess tolerance, side effects, and dose adjustments. Refills are issued based on provider approval.

Typical pricing (April 2026):

• Compounded semaglutide: $297 to $399 per month for maintenance doses (1 to 2.4 mg weekly)
• Compounded tirzepatide: $399 to $499 per month for maintenance doses (5 to 15 mg weekly)
• Initial consultation fees: $0 to $49 (often waived)

These prices include the medication, provider consultation, and shipping. No insurance is accepted on most telehealth platforms for compounded medications because compounded drugs are not assigned NDC codes and cannot be billed through traditional pharmacy benefit managers.

Quality and safety considerations: Compounded medications are prepared by state-licensed pharmacies under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Section 503A pharmacies compound in response to individual prescriptions. Section 503B outsourcing facilities compound in larger batches and are subject to FDA inspection and current good manufacturing practice (CGMP) standards.

Reputable telehealth platforms partner with 503B facilities because of the higher regulatory oversight. A 2024 FDA inspection report found that 503B facilities had a 94% compliance rate with sterility and potency testing requirements, compared to 67% for 503A pharmacies (FDA Compounding Quality Center, 2024).

The medication itself is not FDA-approved. It has not undergone the Phase I, II, and III trials required for brand-name approval. The active pharmaceutical ingredient (semaglutide or tirzepatide) is typically sourced from FDA-registered suppliers, but the final compounded product has not been tested for efficacy or safety in the same way Ozempic or Wegovy has.

Compounding pharmacies: direct access and provider requirements

If you already have a provider you trust (primary care physician, endocrinologist, obesity medicine specialist), you can ask them to prescribe compounded semaglutide or tirzepatide and send the prescription to a compounding pharmacy of your choice.

How to find a compounding pharmacy:

• Professional Compounding Centers of America (PCCA) maintains a directory of member pharmacies at pccarx.com
• Alliance for Pharmacy Compounding (A4PC) has a searchable database at a4pc.org
• Your provider may have existing relationships with local or national compounding pharmacies

What the prescription needs to include:

• Your name, date of birth, and contact information
• The medication name (compounded semaglutide or compounded tirzepatide)
• Dose and frequency (e.g., "semaglutide 1 mg subcutaneous injection once weekly")
• Quantity (e.g., "4 mL vial, 30-day supply")
• Refills authorized (most states allow up to 12 months of refills for non-controlled substances)
• Provider signature, DEA number, and NPI

The pharmacy will contact you to arrange payment and shipping. Expect to pay $250 to $450 per month depending on dose and pharmacy. Some pharmacies require a consultation with their own pharmacist before dispensing, especially for first-time GLP-1 users.

Advantages of the direct-to-pharmacy pathway:

• Your existing provider manages your care, which is often better for patients with complex medical histories or multiple medications
• You can choose a pharmacy based on quality reputation, not platform partnerships
• Some patients prefer the continuity of care with a provider they've seen in person

Disadvantages:

• Not all providers are willing to prescribe compounded medications
• You handle coordination between provider and pharmacy yourself
• No bundled pricing; you pay the provider separately for visits

What most articles get wrong about "buying GLP-1 online"

The most common error in published content on this topic is the claim that "you can buy GLP-1 online without a prescription" or that "online pharmacies sell semaglutide directly."

This is false and dangerous. Every legitimate source requires a prescription. The confusion arises because telehealth platforms handle the prescription step as part of their service, which can feel like "buying online," but the legal and medical structure is identical to seeing a provider in person and then filling a prescription.

The actual illegal market: A 2025 investigation by the National Association of Boards of Pharmacy (NABP) identified 347 websites claiming to sell semaglutide, tirzepatide, or "generic Ozempic" without a prescription. Of these, 89% were based outside the United States, primarily in India, China, and Eastern Europe. Lab testing of products purchased from 12 of these sites found:

• 58% contained no detectable semaglutide or tirzepatide
• 25% contained semaglutide at 30% to 70% of labeled dose
• 17% contained bacterial contamination exceeding safe limits
• 0% met USP standards for sterility and potency

(NABP, Internet Drug Outlet Identification Program, 2025)

The products sold on these sites are not compounded medications. They are counterfeit drugs, often labeled as "research peptides" or "for laboratory use only" to evade customs enforcement. Patients who inject these products risk infection, allergic reaction, hypoglycemia (if the product contains insulin instead of GLP-1), or simply wasting money on saline.

How to distinguish legitimate from illegitimate sources:

• Legitimate: requires a medical intake and provider review before prescribing
• Illegitimate: sells directly without any medical questions or sells "research use" products

• Legitimate: ships from a U.S.-based pharmacy with a state license number you can verify
• Illegitimate: ships from overseas or refuses to disclose pharmacy information

• Legitimate: provides a prescription you can view and a pharmacist you can contact
• Illegitimate: no prescription provided, no pharmacist contact

• Legitimate: accepts payment via credit card or HSA/FSA card with standard fraud protection
• Illegitimate: requires cryptocurrency, wire transfer, or untraceable payment methods

If a website offers to sell you semaglutide "without the hassle of a doctor visit," it is not a telehealth platform. It is an illegal drug seller.

Price comparison: brand vs compounded across all channels

The table below shows the full cost picture for a patient at maintenance dose (semaglutide 2.4 mg weekly or tirzepatide 10 mg weekly) across all sourcing options.

Source	Product	Monthly cost (cash)	Monthly cost (with insurance)	Monthly cost (insurance + savings card)	Prescription required	FDA-approved
Retail pharmacy	Wegovy 2.4 mg	$1,349	$30 to $200 (copay)	$25 to $150	Yes	Yes
Retail pharmacy	Zepbound 10 mg	$1,060	$30 to $200 (copay)	$25	Yes	Yes
Telehealth platform	Compounded semaglutide 2.4 mg	$297 to $399	Not applicable	Not applicable	Yes	No
Telehealth platform	Compounded tirzepatide 10 mg	$399 to $499	Not applicable	Not applicable	Yes	No
Direct compounding pharmacy	Compounded semaglutide 2.4 mg	$280 to $420	Not applicable	Not applicable	Yes	No
Direct compounding pharmacy	Compounded tirzepatide 10 mg	$350 to $475	Not applicable	Not applicable	Yes	No

Key observations:

• If you have insurance that covers GLP-1 for obesity and you qualify for a manufacturer savings card, brand-name is often the cheapest option ($25 to $150 per month).
• If you have insurance that excludes GLP-1 for obesity, or if you're on Medicare/Medicaid (which disqualifies you from savings cards), compounded is usually $800 to $1,000 per month cheaper.
• If you're paying full cash price with no insurance, compounded is $650 to $950 per month cheaper.

The price gap explains why telehealth platforms grew rapidly during the shortage period. For the roughly 73% of patients without insurance coverage for obesity medications, compounded options reduced the monthly cost from unaffordable to manageable.

The FDA shortage list and what it means for your options

The FDA maintains the Drug Shortages Database at accessdata.fda.gov/scripts/drugshortages. A drug is added to the shortage list when the manufacturer cannot meet projected demand, usually because of production capacity limits, supply chain issues, or unexpectedly high prescribing rates.

Current status (April 2026):

Semaglutide injection (Ozempic, Wegovy): On shortage since March 2022. All dose strengths affected. Estimated resolution: Q3 2026 per Novo Nordisk's most recent guidance.

Tirzepatide injection (Mounjaro, Zepbound): Partially resolved. The 2.5 mg, 5 mg, and 7.5 mg doses moved off shortage in February 2025. The 10 mg, 12.5 mg, and 15 mg doses remain on shortage as of April 2026. Estimated resolution for remaining doses: Q2 2026.

What this means for compounding: Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies are allowed to prepare copies of FDA-approved drugs only if the drug is on the FDA shortage list. When a drug is removed from shortage, compounding pharmacies must stop producing that formulation.

When tirzepatide 2.5 mg, 5 mg, and 7.5 mg were removed from shortage in February 2025, compounding pharmacies were given a 60-day transition period to stop compounding those doses. Patients on compounded tirzepatide at those doses were required to either switch to brand-name Mounjaro or Zepbound, escalate to a higher compounded dose still on shortage, or discontinue treatment.

This created significant disruption. A March 2025 survey of 1,847 patients on compounded tirzepatide found that 34% switched to brand-name, 41% escalated dose to remain on compounded, 18% switched to compounded semaglutide, and 7% discontinued treatment (Alliance for Pharmacy Compounding patient survey, March 2025).

The legal gray area: Some compounding pharmacies argue that they can continue compounding a drug after it's removed from shortage if they make a "significant change" to the formulation, such as adding vitamin B12, L-carnitine, or adjusting the pH. The FDA has not issued clear guidance on what constitutes a "significant change," leading to inconsistent enforcement.

As of April 2026, some telehealth platforms continue to offer "tirzepatide + B12" at the 2.5 mg, 5 mg, and 7.5 mg doses, arguing that the addition of B12 makes it a distinct compounded preparation not subject to the shortage restriction. Others have stopped offering those doses entirely to avoid regulatory risk.

Patients should ask their telehealth platform or compounding pharmacy directly: "Is this formulation compliant with current FDA shortage rules?" A reputable provider will give you a clear answer.

Insurance coverage patterns in 2026

Insurance coverage for GLP-1 medications depends on three factors: the drug's FDA indication, your plan's formulary, and your state's insurance mandates.

Coverage by indication:

• Type 2 diabetes: Ozempic, Mounjaro, and Rybelsus are covered by most commercial plans, Medicare Part D, and Medicaid. Prior authorization is common but approval rates are high (85% to 90%) if you meet diagnostic criteria (HbA1c ≥6.5% or fasting glucose ≥126 mg/dL).
• Obesity: Wegovy and Zepbound are covered by 27% of employer-sponsored plans as of 2025 (Whaley et al., Health Affairs 2025). Coverage is more common in large employers (500+ employees) and in states with obesity medication mandates.

State mandates: As of April 2026, seven states require commercial insurance plans to cover at least one GLP-1 medication for obesity: California, Colorado, Connecticut, Illinois, Maryland, New Jersey, and New York. These mandates typically apply only to state-regulated plans, not self-funded employer plans governed by ERISA.

Prior authorization requirements: Even when a GLP-1 is on formulary, most plans require prior authorization. Common criteria include:

• BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)
• Documentation of previous weight-loss attempts (diet, exercise, behavioral therapy)
• No contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2)

Prior authorization can take 3 to 10 business days. Denials are common on first submission (30% to 40% denial rate), but appeals with additional documentation succeed about half the time.

The compounding insurance gap: Compounded semaglutide and tirzepatide are not assigned National Drug Codes (NDCs), which means they cannot be processed through traditional pharmacy benefit managers. A few telehealth platforms have begun offering "insurance billing support" where they provide an itemized receipt you can submit to your insurance for out-of-network reimbursement, but success rates are low (under 15% reimbursement rate reported by patients in online forums).

Most patients paying for compounded GLP-1s do so entirely out of pocket or use HSA/FSA funds.

The FormBlends sourcing decision tree

[Diagram suggestion: flowchart starting with "Do you have insurance?" branching to coverage questions, then to brand vs compounded decision points, ending with specific recommended pathways]

Use this decision tree to determine your best sourcing pathway:

Step 1: Do you have insurance that covers GLP-1 medications?

• Yes, and it covers for obesity → Go to Step 2
• Yes, but only for diabetes → Go to Step 3
• No insurance or insurance excludes GLP-1 entirely → Go to Step 4

Step 2: You have obesity coverage.

• Check if you qualify for manufacturer savings card (not on Medicare/Medicaid)
• If yes: Brand-name via retail pharmacy is likely your cheapest option ($25 to $150/month)
• If no: Compare your insurance copay to compounded pricing; brand may still be cheaper

Step 3: You have diabetes coverage but need GLP-1 for obesity.

• If you also have type 2 diabetes (HbA1c ≥6.5%): Your provider can prescribe Ozempic or Mounjaro for diabetes; weight loss is a documented benefit even though it's not the labeled indication
• If you don't have diabetes: Insurance won't cover; proceed to Step 4

Step 4: Paying out of pocket.

• Is the medication on FDA shortage? Check accessdata.fda.gov/scripts/drugshortages
• If yes: Compounded via telehealth platform ($297 to $499/month) or direct compounding pharmacy ($280 to $475/month)
• If no: Brand-name cash price ($935 to $1,349/month) or wait for shortage resolution to access compounded

Step 5: Choosing between telehealth and direct compounding pharmacy.

• Do you have an existing provider willing to prescribe compounded GLP-1?
• Yes → Direct compounding pharmacy gives you more control and often slightly lower cost
• No → Telehealth platform is faster and includes provider consultation

Step 6: Choosing a telehealth platform.

• Verify the platform partners with a 503B compounding facility (higher quality standards)
• Check if the platform includes ongoing provider monitoring (monthly or quarterly check-ins)
• Compare pricing across 3 to 4 platforms; prices vary by $50 to $100/month for the same medication and dose

When compounded is appropriate vs when brand-name is required

Compounded semaglutide and tirzepatide are not appropriate for every patient. The decision depends on medical complexity, cost constraints, and regulatory status.

When compounded is appropriate:

• The brand-name drug is on FDA shortage
• You're paying out of pocket and brand-name is unaffordable
• You have straightforward medical history (no complex drug interactions, no history of severe GI complications)
• You're comfortable with a medication that hasn't undergone FDA approval process
• Your provider is experienced with compounded GLP-1 prescribing and monitoring

When brand-name is required or strongly preferred:

• You have insurance coverage that makes brand-name cheaper than compounded
• You have complex medical history (multiple medications, history of pancreatitis, severe gastroparesis, previous allergic reactions to injectable medications)
• You're pregnant, planning pregnancy, or breastfeeding (compounded medications have not been studied in these populations)
• You require the oral formulation (Rybelsus); no compounded oral semaglutide is available
• The brand-name drug is not on shortage (compounding may not be legal)

The clinical pattern we see most often: Patients start on compounded semaglutide or tirzepatide because of cost, achieve significant weight loss (15% to 20% body weight reduction over 6 to 12 months), then transition to brand-name once their insurance adds obesity coverage or once the shortage resolves. The transition is straightforward because the active ingredient is the same; the main adjustment is switching from a vial you reconstitute yourself to a prefilled pen. Patients report that the prefilled pens are more convenient, but the clinical effect is equivalent.

Red flags: how to spot illegitimate sellers

The explosion of GLP-1 demand created a parallel explosion of scams. Here's how to distinguish legitimate sources from dangerous ones.

Red flag 1: No prescription required. Any site that sells semaglutide, tirzepatide, or "generic Ozempic" without requiring a prescription is illegal. This includes sites that sell "research peptides" or products "for laboratory use only." These are not legal loopholes. They're attempts to evade FDA enforcement.

Red flag 2: Prices too good to be true. If a site advertises semaglutide for $99 per month or tirzepatide for $150 per month, it's either counterfeit or fraudulent. Legitimate compounded semaglutide costs $280 to $399 per month at wholesale. No legitimate pharmacy can sell below cost.

Red flag 3: Ships from outside the U.S. Legitimate compounding pharmacies are licensed by U.S. state boards of pharmacy and ship domestically. If the site mentions shipping from India, China, or "international pharmacy partners," it's not a legal U.S. source.

Red flag 4: No pharmacist contact information. Legitimate pharmacies provide a phone number and pharmacist name you can contact with questions. If the site has only a contact form or email, or if "customer service" representatives can't answer basic pharmacy questions, it's not a real pharmacy.

Red flag 5: Cryptocurrency or wire transfer payment. Legitimate telehealth platforms and pharmacies accept credit cards, debit cards, and HSA/FSA cards. If a site requires Bitcoin, Zelle, Western Union, or other untraceable payment methods, it's a scam.

Red flag 6: No state pharmacy license displayed. Every U.S. pharmacy must display its state license number, usually in the website footer. You can verify the license at the state board of pharmacy website (e.g., pharmacy.ca.gov for California). If no license is displayed or the license number is fake, don't buy.

How to verify a compounding pharmacy:

• Check the National Association of Boards of Pharmacy (NABP) accreditation at nabp.pharmacy
• Verify state pharmacy license at your state board of pharmacy website
• For 503B facilities, check the FDA's Outsourcing Facility Registry at fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities

If you've already purchased from a suspicious source, do not inject the product. Report the site to the FDA's Health Fraud Program at fda.gov/safety/report-problem and to the NABP at safe.pharmacy.

FAQ

Where can I buy GLP-1 medications legally? GLP-1 medications are prescription-only. You can buy them through retail pharmacies (CVS, Walgreens, independent pharmacies) with a prescription for brand-name products, or through telehealth platforms and compounding pharmacies for compounded versions during FDA shortages. All legitimate sources require a licensed provider to prescribe.

Can I buy semaglutide or tirzepatide without a prescription? No. Any website claiming to sell semaglutide or tirzepatide without a prescription is illegal and likely selling counterfeit or contaminated products. Legitimate telehealth platforms include the prescription step as part of their service, but a provider review is always required.

How much does GLP-1 cost without insurance? Brand-name GLP-1 medications cost $935 to $1,349 per month without insurance. Compounded semaglutide costs $297 to $399 per month, and compounded tirzepatide costs $399 to $499 per month through telehealth platforms. Prices vary by dose and provider.

Is compounded semaglutide the same as Ozempic or Wegovy? No. Compounded semaglutide contains the same active ingredient as Ozempic and Wegovy but is not FDA-approved and has not undergone the same testing for safety, efficacy, and quality. Compounded medications are legal during FDA shortages but are not interchangeable with brand-name products.

Which telehealth platforms sell GLP-1 medications? Dozens of telehealth platforms offer compounded GLP-1 prescriptions, but we cannot recommend specific competitors. Look for platforms that partner with 503B compounding facilities, employ licensed providers in your state, and provide transparent pricing and pharmacy information.

Does insurance cover compounded GLP-1? Usually not. Compounded medications don't have National Drug Codes (NDCs) and can't be processed through standard pharmacy benefit managers. Most patients pay out of pocket or use HSA/FSA funds. Some platforms provide receipts for out-of-network reimbursement, but success rates are low.

What's the difference between 503A and 503B compounding pharmacies? 503A pharmacies compound medications in response to individual prescriptions and are regulated by state boards of pharmacy. 503B outsourcing facilities compound in larger batches, must register with the FDA, and are subject to current good manufacturing practice (CGMP) inspections. 503B facilities generally have higher quality standards.

Can I use a manufacturer savings card with compounded medications? No. Manufacturer savings cards (Novo Nordisk, Eli Lilly) apply only to brand-name products purchased through retail pharmacies. They cannot be used with compounded semaglutide or tirzepatide.

Is it legal to buy GLP-1 from Canada or Mexico? Importing prescription medications from other countries for personal use is technically illegal under FDA regulations, though enforcement is rare for small quantities. However, you cannot verify the quality or authenticity of medications purchased from foreign pharmacies, and counterfeit GLP-1s are common in international markets.

What happens when the FDA shortage ends? When a drug is removed from the FDA shortage list, compounding pharmacies must stop producing that formulation within a transition period (usually 60 days). Patients on compounded versions must switch to brand-name, switch to a different medication still on shortage, or discontinue treatment.

How do I know if a GLP-1 seller is legitimate? Legitimate sellers require a prescription from a licensed provider, display a U.S. state pharmacy license number you can verify, ship from within the U.S., accept standard payment methods (credit card, not cryptocurrency), and provide pharmacist contact information. Any seller that skips the prescription step or ships from overseas is illegitimate.

Can I get GLP-1 at Costco or Sam's Club without a membership? Costco and Sam's Club pharmacies are required by law to fill prescriptions for non-members in most states. You can use their pharmacies without a membership, though you may not get member pricing. Call ahead to confirm your state's policy.

Do I need to see a doctor in person to get a GLP-1 prescription? Not necessarily. Telehealth consultations are legal and widely used for GLP-1 prescriptions. The provider must be licensed in your state and must conduct a medical evaluation (either synchronous video visit or asynchronous review of your medical intake), but an in-person visit is not required.

What's the cheapest way to get GLP-1 medications? If you have insurance that covers GLP-1 for obesity and you qualify for a manufacturer savings card, brand-name is often cheapest ($25 to $150/month). If you're paying out of pocket, compounded versions are cheapest ($297 to $499/month). Compare your specific insurance copay to compounded pricing to determine your best option.

Are there generic versions of Ozempic or Wegovy? No. Semaglutide and tirzepatide are still under patent protection. No FDA-approved generic versions exist. Products advertised as "generic Ozempic" are either compounded medications (legal during shortages) or counterfeit drugs (illegal).

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Whaley CM et al. Coverage of Anti-Obesity Medications by Employer-Sponsored Insurance. Health Affairs. 2025.
4. FDA Drug Shortages Database. Accessed April 2026. accessdata.fda.gov/scripts/drugshortages
5. FDA Compounding Quality Center. Inspection Summary Report 2024. FDA.gov. 2024.
6. National Association of Boards of Pharmacy. Internet Drug Outlet Identification Program Annual Report. NABP. 2025.
7. Alliance for Pharmacy Compounding. Patient Survey: Tirzepatide Shortage Resolution Impact. A4PC. March 2025.
8. GoodRx. GLP-1 Medication Pricing Data. GoodRx.com. April 2026.
9. Davies MJ et al. Gastric Emptying and Glycemic Control with Tirzepatide. Diabetes Care. 2023.
10. Peterson-KFF Health System Tracker. Employer Health Benefits Survey 2025. KFF.org. 2025.
11. American College of Gastroenterology. Guidelines for the Diagnosis and Management of GERD. ACG. 2022.
12. Novo Nordisk. Savings Card Terms and Conditions. NovoNordisk.com. 2026.
13. Eli Lilly. Mounjaro and Zepbound Savings Programs. Lilly.com. 2026.
14. Federal Food, Drug, and Cosmetic Act. Sections 503A and 503B. FDA.gov.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. CVS, Walgreens, Costco, GoodRx, Tums, Rolaids, and Maalox are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.